Posted by Michael Wonder on 12 Dec 2019
Decision to award sole supply for fluticasone and fluticasone with salmeterol metered dose inhalers
12 December 2019 - PHARMAC has made a decision to make changes to the funded brands of fluticasone and fluticasone with salmeterol metered dose inhalers, which are used in the management of asthma and chronic obstructive pulmonary disease.
This decision means that the Flixotide brand of fluticasone metered dose inhaler (MDI) and the Seretide brand of fluticasone with salmeterol MDI, which are currently funded and supplied by GlaxoSmithKline, will be the only funded brands of fluticasone and fluticasone with salmeterol MDIs from 1 September 2020 until at least 30 June 2023.
